Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study-Reference-Cited by-同舟云学术

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study

Published:2012-11-20 Issue:1 Volume:13 Page:
ISSN:1471-2369
Container-title:BMC Nephrology
language:en
Short-container-title:BMC Nephrol

Author:

De Nicola Luca,Conte Giuseppe,Russo Domenico,Gorini Antonio,Minutolo Roberto

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/article/10.1186/1471-2369-13-150/fulltext.html

Reference34 articles.

1. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009, 54: 205-226. 10.1053/j.ajkd.2009.04.029.

2. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R, SIN-TABLE CKD Study Group: Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol. 2011, 6: 2421-2428. 10.2215/CJN.01180211.

3. Ruggenenti P, Perna A, Remuzzi G, GISEN Group Investigators: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 2003, 63: 2254-2261. 10.1046/j.1523-1755.2003.00033.x.

4. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004, 110: 921-927. 10.1161/01.CIR.0000139860.33974.28.

5. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007, 18: 1540-1546. 10.1681/ASN.2006050445.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiproteinuric effect of paricalcitol in kidney transplant recipients with severe proteinuria: a prospective cohort study;Journal of Nephrology;2022-07-28

2. Antiproteinuria Effect of Calcitriol in Patients With Chronic Kidney Disease and Vitamin D Deficiency: A Randomized Controlled Study;Journal of Renal Nutrition;2020-05

3. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria;International Urology and Nephrology;2019-11-25

4. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism;European Journal of Pharmacology;2019-02

5. Acute kidney injury and disease: Long-term consequences and management;Nephrology;2018-10-25